JP2017036288A5 - - Google Patents

Download PDF

Info

Publication number
JP2017036288A5
JP2017036288A5 JP2016175431A JP2016175431A JP2017036288A5 JP 2017036288 A5 JP2017036288 A5 JP 2017036288A5 JP 2016175431 A JP2016175431 A JP 2016175431A JP 2016175431 A JP2016175431 A JP 2016175431A JP 2017036288 A5 JP2017036288 A5 JP 2017036288A5
Authority
JP
Japan
Prior art keywords
inhibitor
subject
administered
use according
jak
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016175431A
Other languages
English (en)
Japanese (ja)
Other versions
JP6375345B2 (ja
JP2017036288A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2017036288A publication Critical patent/JP2017036288A/ja
Publication of JP2017036288A5 publication Critical patent/JP2017036288A5/ja
Application granted granted Critical
Publication of JP6375345B2 publication Critical patent/JP6375345B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016175431A 2011-04-28 2016-09-08 Ｈｓｐ９０併用療法 Expired - Fee Related JP6375345B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161480198P 2011-04-28 2011-04-28
US61/480,198 2011-04-28

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2014508165A Division JP6363502B2 (ja) 2011-04-28 2012-04-27 Ｈｓｐ９０併用療法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018106047A Division JP2018153194A (ja) 2011-04-28 2018-06-01 Ｈｓｐ９０併用療法

Publications (3)

Publication Number Publication Date
JP2017036288A JP2017036288A (ja) 2017-02-16
JP2017036288A5 true JP2017036288A5 (OSRAM) 2017-07-13
JP6375345B2 JP6375345B2 (ja) 2018-08-15

Family

ID=47073116

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2014508165A Expired - Fee Related JP6363502B2 (ja) 2011-04-28 2012-04-27 Ｈｓｐ９０併用療法
JP2016175431A Expired - Fee Related JP6375345B2 (ja) 2011-04-28 2016-09-08 Ｈｓｐ９０併用療法
JP2018106047A Withdrawn JP2018153194A (ja) 2011-04-28 2018-06-01 Ｈｓｐ９０併用療法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2014508165A Expired - Fee Related JP6363502B2 (ja) 2011-04-28 2012-04-27 Ｈｓｐ９０併用療法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018106047A Withdrawn JP2018153194A (ja) 2011-04-28 2018-06-01 Ｈｓｐ９０併用療法

Country Status (12)

Country Link
US (2) US20140315929A1 (OSRAM)
EP (1) EP2701747A4 (OSRAM)
JP (3) JP6363502B2 (OSRAM)
KR (2) KR102027448B1 (OSRAM)
CN (2) CN109498812A (OSRAM)
AU (3) AU2012249322B2 (OSRAM)
BR (1) BR112013027448A2 (OSRAM)
CA (1) CA2833390A1 (OSRAM)
EA (1) EA201391587A1 (OSRAM)
MX (1) MX2013012183A (OSRAM)
NZ (1) NZ618062A (OSRAM)
WO (1) WO2012149493A2 (OSRAM)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104081203B (zh) 2011-07-08 2018-07-31 索隆-基特林癌症研究协会 标记的hsp90抑制剂的用途
US20140079636A1 (en) * 2012-04-16 2014-03-20 Dinesh U. Chimmanamada Targeted therapeutics
WO2014100719A2 (en) 2012-12-21 2014-06-26 Epizyme, Inc. Prmt5 inhibitors and uses thereof
WO2015089402A1 (en) * 2013-12-12 2015-06-18 The University Of Chicago Methods and compositions related to hsp90 inhibitors and breast cancer
EP3086792B1 (en) 2013-12-23 2022-10-12 Memorial Sloan-Kettering Cancer Center Methods and reagents for radiolabeling
CA2947604A1 (en) * 2014-05-02 2015-11-05 The Wistar Institute Of Anatomy And Biology Combination therapies targeting mitochondria for cancer therapy
EA201790444A1 (ru) 2014-09-17 2017-08-31 Мемориал Слоун Кеттеринг Кэнсэ Сентр Hsp90-направленная визуализация и терапия воспаления и инфекции
US10265009B2 (en) 2014-10-21 2019-04-23 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for conditions associated with microbiome taxonomic features
CN107075588B (zh) 2014-10-21 2023-03-21 普梭梅根公司 用于微生物组来源的诊断和治疗的方法及系统
US10409955B2 (en) 2014-10-21 2019-09-10 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for locomotor system conditions
US10388407B2 (en) 2014-10-21 2019-08-20 uBiome, Inc. Method and system for characterizing a headache-related condition
US10169541B2 (en) 2014-10-21 2019-01-01 uBiome, Inc. Method and systems for characterizing skin related conditions
US10793907B2 (en) 2014-10-21 2020-10-06 Psomagen, Inc. Method and system for microbiome-derived diagnostics and therapeutics for endocrine system conditions
US10366793B2 (en) 2014-10-21 2019-07-30 uBiome, Inc. Method and system for characterizing microorganism-related conditions
US10395777B2 (en) 2014-10-21 2019-08-27 uBiome, Inc. Method and system for characterizing microorganism-associated sleep-related conditions
US10777320B2 (en) 2014-10-21 2020-09-15 Psomagen, Inc. Method and system for microbiome-derived diagnostics and therapeutics for mental health associated conditions
US10325685B2 (en) 2014-10-21 2019-06-18 uBiome, Inc. Method and system for characterizing diet-related conditions
US9754080B2 (en) 2014-10-21 2017-09-05 uBiome, Inc. Method and system for microbiome-derived characterization, diagnostics and therapeutics for cardiovascular disease conditions
US9710606B2 (en) 2014-10-21 2017-07-18 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for neurological health issues
US10381112B2 (en) 2014-10-21 2019-08-13 uBiome, Inc. Method and system for characterizing allergy-related conditions associated with microorganisms
US10073952B2 (en) 2014-10-21 2018-09-11 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for autoimmune system conditions
US11783914B2 (en) 2014-10-21 2023-10-10 Psomagen, Inc. Method and system for panel characterizations
US9760676B2 (en) 2014-10-21 2017-09-12 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for endocrine system conditions
US10357157B2 (en) 2014-10-21 2019-07-23 uBiome, Inc. Method and system for microbiome-derived characterization, diagnostics and therapeutics for conditions associated with functional features
US9758839B2 (en) 2014-10-21 2017-09-12 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for conditions associated with microbiome functional features
US10311973B2 (en) 2014-10-21 2019-06-04 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for autoimmune system conditions
US10410749B2 (en) 2014-10-21 2019-09-10 uBiome, Inc. Method and system for microbiome-derived characterization, diagnostics and therapeutics for cutaneous conditions
US10789334B2 (en) 2014-10-21 2020-09-29 Psomagen, Inc. Method and system for microbial pharmacogenomics
US10346592B2 (en) 2014-10-21 2019-07-09 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for neurological health issues
US10246753B2 (en) 2015-04-13 2019-04-02 uBiome, Inc. Method and system for characterizing mouth-associated conditions
WO2016168344A1 (en) * 2015-04-13 2016-10-20 uBiome, Inc. Method and system for microbiome-derived characterization, diaganostics and therapeutics for conditions associated with functional features
CN106265660B (zh) * 2015-05-21 2019-08-02 中国科学院合肥物质科学研究院 A674563在携带flt3突变型基因的急性白血病中的用途
CN106349180B (zh) * 2015-07-14 2020-05-19 上海翰森生物医药科技有限公司 4,5-二苯基异噁唑衍生物及其制备方法和应用
US11319376B2 (en) * 2016-08-03 2022-05-03 Remd Biotherapeutics, Inc. Combination of glucagon receptor antagonists and PI3K pathway inhibitors for the treatment of cancer
MX2019009227A (es) 2017-02-03 2020-02-12 Ai Therapeutics Inc Métodos para tratar cáncer con inhibidores de hsp90.
AU2018289349A1 (en) 2017-06-20 2020-01-02 Madrigal Pharmaceuticals, Inc. Combination therapies comprising targeted therapeutics
KR20200016875A (ko) 2017-06-20 2020-02-17 마드리갈 파마슈티칼스 인코포레이티드 표적화 치료제
EP3891123A4 (en) 2018-12-03 2022-12-14 Board of Regents, The University of Texas System ANALOGS OF OLIGO-BENZAMIDE AND THEIR USE IN THE TREATMENT OF CANCER
CN109554343B (zh) * 2018-12-29 2022-04-19 吉林大学 一种适于神经元粘附与存活的涂层材料及制备方法
CN111467472B (zh) * 2020-04-21 2020-12-25 南京中医药大学 一种靶向肿瘤相关巨噬细胞的免疫调节微球制剂及其制备方法与应用
US20230218577A1 (en) * 2020-06-11 2023-07-13 The Children's Medical Center Corporation Use of heat shock protein inhibitors for the treatment of neurodevelopmental disorders
CN116615422A (zh) * 2020-10-14 2023-08-18 珃诺生物医药科技(杭州)有限公司 用于靶向蛋白降解的方法和组合物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303652B1 (en) * 1998-08-21 2001-10-16 Hughes Institute BTK inhibitors and methods for their identification and use
WO2007035963A2 (en) 2005-09-23 2007-03-29 Conforma Therapeutics Corporation Anti-tumor methods using multi drug resistance independent synthetic hsp90 inhibitors
WO2008044029A1 (en) * 2006-10-12 2008-04-17 Astex Therapeutics Limited Pharmaceutical combinations
EP2120900A2 (en) * 2007-02-15 2009-11-25 Novartis AG Combination of lbh589 with other therapeutic agents for treating cancer
WO2008114812A1 (ja) * 2007-03-19 2008-09-25 Kyowa Hakko Kirin Co., Ltd. Jak阻害剤
AU2008282338B2 (en) * 2007-07-30 2015-02-12 Ardea Biosciences, Inc. Derivatives of N-(arylamino) sulfonamides including polymorphs as inhibitors of MEK as well as compositions, methods of use and methods for preparing the same
WO2009073575A2 (en) * 2007-11-30 2009-06-11 Oregon Health & Science University Methods for treating induced cellular proliferative disorders
US20110224223A1 (en) * 2008-07-08 2011-09-15 The Regents Of The University Of California, A California Corporation MTOR Modulators and Uses Thereof
WO2010020618A1 (en) * 2008-08-18 2010-02-25 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Susceptibility to hsp90-inhibitors
DK2370076T3 (en) * 2008-11-28 2017-04-03 Novartis Ag Pharmaceutical combination comprising an Hsp 90 inhibitor and an mTOR inhibitor
US8669289B2 (en) * 2009-04-24 2014-03-11 The Jackson Laboratory Methods and compositions relating to hematologic malignancies
JP5744859B2 (ja) * 2009-06-15 2015-07-08 ライジェル ファーマシューティカルズ， インコーポレイテッド 脾臓チロシンキナーゼ（ｓｙｋ）の小分子阻害薬
CN108752280A (zh) * 2009-08-17 2018-11-06 纪念斯隆-凯特琳癌症中心 热休克蛋白结合化合物、组合物以及其制备和使用方法
JP2013510585A (ja) * 2009-11-13 2013-03-28 インフィニティー ファーマシューティカルズ， インコーポレイテッド 癌の同定、評価、予防および治療のための組成物、キットおよび方法
KR101580714B1 (ko) * 2010-06-03 2016-01-04 파마싸이클릭스 엘엘씨 브루톤 티로신 인산화효소(ｂｔｋ)의 억제제의 용도
WO2012162372A1 (en) * 2011-05-24 2012-11-29 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitory compounds with mtor/p13k inhibitors

Similar Documents

Publication Publication Date Title
JP2017036288A5 (OSRAM)
JP2019068829A5 (OSRAM)
JP2016508134A5 (OSRAM)
MX2024010140A (es) Nuevos metodos.
CN113767106A (zh) 氧杂氮杂喹唑啉-7(8h)-酮类化合物,其制法与医药上的用途
FI3265084T3 (fi) Brutonin tyrosiinikinaasin estäjän lääkeformulaatioita
JP2016163571A5 (OSRAM)
MX2021002322A (es) Nuevos metodos.
EP4628100A3 (en) Anti-viral compounds and methods for administration thereof
NO20092585L (no) Forbindelser og farmasoytiske sammensetninger for behandling av virale infeksjoner
ME02400B (me) Policiklična karbamoilpiridonska jedinjenja i njihova farmaceutska upotreba
MX383665B (es) Composiciones de donepezilo y métodos para tratar la enfermedad de alzheimer.
WO2020115555A3 (en) Crf1 receptor antagonist, pharmaceutical formulations and solid forms thereof for the treatment of congenital adrenal hyperplasia
ES2527544T1 (es) Tratamiento mono (PSI-7977) o de combinación con AAD para su uso en el tratamiento del VHC
JP2018521993A5 (OSRAM)
IL295418B1 (en) Beta-d-2'-deoxy-2' alpha-fluoro-2'-bata-c-modified-2-different-n6-purine modified nucleotides for the treatment of hepatitis c virus
JP2006508953A5 (OSRAM)
JP2016147915A5 (OSRAM)
PA8744101A1 (es) Metodo de terapia combinada para el tratamiento de la infeccion por el virus de la hepatitis c y composiciones farmaceuticas para usar en dicha terapia
JP2020529995A5 (OSRAM)
MX389088B (es) Métodos para tratar el vhc.
JP2006507295A5 (OSRAM)
WO2023043830A1 (en) Combination therapies to treat viral infections
JP2008534621A5 (OSRAM)
CN109689657A (zh) 氘代3-(4,5-取代氨基嘧啶)苯基衍生物及其应用